144 related articles for article (PubMed ID: 33118445)
1. Malignant hyperthermia susceptibility: utilization of genetic results in an electronic medical record to increase safety.
Baye JF; Petry NJ; Jacobson SL; Moore MM; Tucker B; Shaaban S; Massmann AK; Clark NM; Schultz AJ
Pharmacogenomics; 2020 Nov; 21(17):1207-1215. PubMed ID: 33118445
[No Abstract] [Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes.
Gonsalves SG; Dirksen RT; Sangkuhl K; Pulk R; Alvarellos M; Vo T; Hikino K; Roden D; Klein TE; Poler SM; Patel S; Caudle KE; Gordon R; Brandom B; Biesecker LG
Clin Pharmacol Ther; 2019 Jun; 105(6):1338-1344. PubMed ID: 30499100
[TBL] [Abstract][Full Text] [Related]
3. Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients.
Brandom BW; Muldoon SM
Paediatr Anaesth; 2013 Sep; 23(9):851-4. PubMed ID: 23848295
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia.
Beam TA; Loudermilk EF; Kisor DF
Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884
[TBL] [Abstract][Full Text] [Related]
5. Volatile anesthetics and succinylcholine in cardiac ryanodine receptor defects.
Swan H; Laitinen PJ; Toivonen L
Anesth Analg; 2004 Aug; 99(2):435-7, table of contents. PubMed ID: 15271719
[TBL] [Abstract][Full Text] [Related]
6. [Malignant hyperthermia].
Glahn KP
Ugeskr Laeger; 2003 Apr; 165(17):1763-8. PubMed ID: 12768904
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic testing to diagnose malignant hyperthermia susceptibility.
Girard T; Litman RS
J Clin Anesth; 2008 May; 20(3):161-3. PubMed ID: 18502356
[No Abstract] [Full Text] [Related]
8. Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of
Sadhasivam S; Brandom BW; Henker RA; McAuliffe JJ
Pharmacogenomics; 2019 Sep; 20(14):989-1003. PubMed ID: 31559918
[No Abstract] [Full Text] [Related]
9. Genetic epidemiology of malignant hyperthermia in the UK.
Miller DM; Daly C; Aboelsaod EM; Gardner L; Hobson SJ; Riasat K; Shepherd S; Robinson RL; Bilmen JG; Gupta PK; Shaw MA; Hopkins PM
Br J Anaesth; 2018 Oct; 121(4):944-952. PubMed ID: 30236257
[TBL] [Abstract][Full Text] [Related]
10. Using exome data to identify malignant hyperthermia susceptibility mutations.
Gonsalves SG; Ng D; Johnston JJ; Teer JK; Stenson PD; Cooper DN; Mullikin JC; Biesecker LG;
Anesthesiology; 2013 Nov; 119(5):1043-53. PubMed ID: 24195946
[TBL] [Abstract][Full Text] [Related]
11. Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review.
Kraeva N; Sapa A; Dowling JJ; Riazi S
Can J Anaesth; 2017 Jul; 64(7):736-743. PubMed ID: 28326467
[TBL] [Abstract][Full Text] [Related]
12. Suspected malignant hyperthermia during sevoflurane anesthesia.
Hsu SC; Huang WT; Yeh HM; Hsieh AY
J Chin Med Assoc; 2007 Nov; 70(11):507-10. PubMed ID: 18063506
[TBL] [Abstract][Full Text] [Related]
13. [Anesthesia in malignant hyperthermia].
Ortiz Gómez JR
Rev Esp Anestesiol Reanim; 2008 Mar; 55(3):165-74. PubMed ID: 18401991
[TBL] [Abstract][Full Text] [Related]
14. Resequencing array for gene variant detection in malignant hyperthermia and butyrylcholinestherase deficiency.
Levano S; Gonzalez A; Singer M; Demougin P; Rüffert H; Urwyler A; Girard T
Neuromuscul Disord; 2017 May; 27(5):492-499. PubMed ID: 28259615
[TBL] [Abstract][Full Text] [Related]
15. Ring fibers visualized by electron microscopy in a Japanese patient with malignant hyperthermia.
Kitagawa Y; Sato J; Kuriyama M; Sano K; Hashimoto K
Odontology; 2011 Jan; 99(1):101-104. PubMed ID: 21271335
[TBL] [Abstract][Full Text] [Related]
16. Sequence variants in malignant hyperthermia genes in Iceland: classification and actionable findings in a population database.
Fridriksdottir R; Jonsson AJ; Jensson BO; Sverrisson KO; Arnadottir GA; Skarphedinsdottir SJ; Katrinardottir H; Snaebjornsdottir S; Jonsson H; Eiriksson O; Oskarsson GR; Oddsson A; Jonasdottir A; Jonasdottir A; Sigurdsson GH; Indridason EP; Sigurdsson SB; Bjornsdottir G; Saemundsdottir J; Magnusson OT; Bjornsson HT; Thorsteinsdottir U; Sigurdsson TS; Sulem P; Sigurdsson MI; Stefansson K
Eur J Hum Genet; 2021 Dec; 29(12):1819-1824. PubMed ID: 34462577
[TBL] [Abstract][Full Text] [Related]
17. [Atypical malignant hyperthermia. A higher incidence than expected].
Herrero E; Casinello F; de Stefano J; Fernández-Guisasola J; Pérez-Gallardo A
Rev Esp Anestesiol Reanim; 1996 Jan; 43(1):42-3. PubMed ID: 8851836
[No Abstract] [Full Text] [Related]
18. PharmGKB summary: succinylcholine pathway, pharmacokinetics/pharmacodynamics.
Alvarellos ML; McDonagh EM; Patel S; McLeod HL; Altman RB; Klein TE
Pharmacogenet Genomics; 2015 Dec; 25(12):622-30. PubMed ID: 26398623
[No Abstract] [Full Text] [Related]
19. Case report: Death in the emergency department: an unrecognized awake malignant hyperthermia-like reaction in a six-year-old.
Lavezzi WA; Capacchione JF; Muldoon SM; Sambuughin N; Bina S; Steele D; Brandom BW
Anesth Analg; 2013 Feb; 116(2):420-3. PubMed ID: 23267001
[TBL] [Abstract][Full Text] [Related]
20. A genetic mystery in malignant hyperthermia 'solved'?
Schiemann AH; Bjorksten AR; Gillies RL; Hockey BM; Ball C; Pollock N; Bulger T; Stowell KM
Br J Anaesth; 2018 Sep; 121(3):681-682. PubMed ID: 30115273
[No Abstract] [Full Text] [Related]
[Next] [New Search]
